Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Artificial Lungs is a Rapidly Growing Type of Artificial Organs, Global Market is Expected to Grow at a CAGR of 6.7% through 2031

Published

on

PUNE, India, July 07, 2021 (GLOBE NEWSWIRE) — The Global Artificial Lungs Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis.

The artificial lung (AL) is a prosthetic gadget that transfers oxygen to the blood and eliminates carbon dioxide from the blood. Artificial Lungs is expected to replace a fair share of the functions that the natural lung performs in human body in near future. Artificial lung gadgets for quite a long time have been utilized in babies and youngsters with lung disorders namely, pneumonia, meconium inhalation condition and various other respiratory malfunctions.

Along with utilizing conventional procedures (upper bar), artificial lung (AL) support is initiated when the other treatment options, including mechanical ventilation (MV), are of no help in improving the patient’s condition. Respiratory assistance gadgets like artificial lungs could at last get practically importance equivalent to ventricular aiding gadgets. Breethe, Inc. (Baltimore-based clinical gadget organization) acquired restrictive rights of College of Maryland. Breethe, Inc. (Baltimore-based clinical gadget organization) accesses the protected institution of the college involved in the furtherance of a portable, easy to carry, wearable blood siphon oxygenator that will help in betterment of patient encountering cardiopulmonary collapse and respiratory failure.

View the Entire report with Table of Contents: https://www.insightslice.com/artificial-lungs-market

Primary recipients of Artificial Lungs

Patients suffering from End-stage lungs illness, specifically chronic obstructive pulmonary infections (COPD) patients, serious pulmonary hypertension (PAH), Intense respiratory pain disorder (ARDS) are prescribed Artificial lungs.

Advantages of artificial lungs over other devices

Large area diffusion contraptions (micro fluidic lungs) attached with 3D geographical proved to be a progressive leap in the Artificial lungs field and will beat a significant impediment to the clinical application of artificial lungs. Artificial lungs have improved gas movement performance contrasted with current gadgets to allow respiratory help of patients suffering from advanced stages of respiratory illnesses. Another advantage of artificial lungs is expanded biocompatibility to establish gadget lifespan, which lends a helping hand in granting long-term treatment, and progress in patient wellbeing.

Also, expanded convenience to allow mobile or portable treatments and bettered patient personal satisfaction is helping artificial lungs in its growth worldwide.

Access Sample Pages of this Report: https://www.insightslice.com/request-sample/659

Growth driving factors of Artificial Lungs Market

Advancements and research carried out extensively in artificial lung technology innovation, including bettered shapes, improved tubing, and ambulatory aid methods, make it progressively conceivable to help select patients effectively, allowing them to endure the selection for a reasonable donor lung, and, significantly, to accomplish a fruitful post-transplant result.

Recently, enhancements in persistent selection, a superior understanding and further comprehension of ventilator-related lung injuries, and upgrades in artificial lung gadget transformations have made it conceivable to effectively connect patients to healing or to lung transplantation. Rising frequency of respiratory issue and developing issues with lungs has increased evolution of the worldwide artificial lung market. Additionally, it is likewise utilized as an oxygenator while doing cardiovascular medical procedures. Owing to this factor, various organizations are putting forth attempts in creating functional user-friendly oxygenators that are thriving competition in this market.

Analysts and researchers are putting forth diligent attempts in creating and improving artificial lungs, with which it very well may be utilized at bigger scope and with greater comfort.

Major players in the market are additionally putting forth comparative attempts that will profit the development in the worldwide artificial lung market.

The leading market segments of Global Artificial Lungs Market

North America is projected to lead the worldwide artificial lung market during 2020-2030 owing to coronavirus outbreak. Presence of key regional players, expanding endeavors made in clinical innovative work, and high venture made in creating and improving artificial lung has made this region lead the worldwide artificial lung market. Rising attentiveness among people has additionally altered development positively in North America artificial lung market. The rising frequencies of cardiovascular illnesses are required to drive the market over the speculated time frame.

Related report:

Global Entecavir Market: https://www.insightslice.com/entecavir-market   

Global Genomics Market: https://www.insightslice.com/genomics-market   

Global Fabry Disease Treatment Market: https://www.insightslice.com/fabry-disease-treatment-market

As indicated by the American School of Cardiology, cardiovascular illness represented 800,000 mortalities in the US in 2017 alone. Along this very same line of reference, among Americans, a normal of one person dies from cardiovascular infection every 40 seconds. Coronary illness represents most of CVD death counts, trailed by stroke and cardiovascular breakdown.

The key players of the Global Artificial Lungs Market are:

ALung Technologies, Breethe, Haemair, Lung Biotechnology PBC, McGowan Institute for Regenerative Medicine, MedArray, Michigan Critical Care Consultants, Miromatrix Medical, The Charles Stark Draper Laboratory, Xenios.

Buy This Report: https://www.insightslice.com/buy-now/659

Global Artificial Lungs Market Key Segments:

Product Type

  • Single Roller Pump Heart Lung Machines
  • Double Roller Pump Heart Lungs Machines
  • Bubble Artificial Lung
  • Membrane Artificial Lung

Application Type

  • Cardiac Surgery
  • Lung Transplant Operation
  • Acute Respiratory Failure Treatment
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Middle East & Africa
    • UAE
    • South Africa
    • Saudi Arabia
    • Rest of MEA
  • South America
    • Brazil
    • Rest of South America

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at [email protected] .

Contact Us:

Alex,

insightSLICE

Phone (USA): +1 707 736 6633

Email address: [email protected]   

Web: www.insightslice.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Announce Winner of Inaugural 2024 Life Sciences Innovation Summit

Published

on

jp.-morgan-life-sciences-private-capital,-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit

In conjunction with Abu Dhabi Global Healthcare Week 2024
ABU DHABI, UAE, May 17, 2024 /PRNewswire/ — J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Group announced today Rayees Rahman of Harmonic Discovery as the winner of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Harmonic Discovery is a precision pharmacology company applying its generative chemistry platform to advance next-generation kinase inhibitors.

In partnership with the Department of Health – Abu Dhabi (DoH), the Summit took place on May 14-15, 2024 at Cleveland Clinic Abu Dhabi and showcased the 11 innovative finalists, as well as highlighted existing innovators and opportunities in the Emirate of Abu Dhabi. The event also featured keynote speeches from Dr. Laurie Glimcher of Dana-Farber Cancer Institute, Dr. Shahrukh Hashmi of the Department of Health – Abu Dhabi, and Dr. David Ho of Columbia University Medical Center and provided attendees networking opportunities to gain valuable insights into the future of life sciences innovation. 
In addition, the jury designated Chun-Hao Huang of Algen Biotechnologies as honourable mention. Algen Biotechnologies is a platform therapeutics and drug discovery company using world-leading CRISPR and AI to find treatments for cancer, inflammation and metabolic diseases.
The winners were selected by an esteemed, international panel of judges, which included:Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer InstituteJorge Guzman, MD, CEO at Cleveland Clinic Abu DhabiProf. Shahrukh Khurshid Hashmi, MD, Director of Research, Department of Health, Abu DhabiYasmine Hayek Kobeissi, PhD, CQF, BSc., Executive Director at Blue Horizon AdvisorsAnya Schiess, Managing Partner at J.P. Morgan Life Sciences Private CapitalWalid Zaher, PhD, Co-Founder and CEO, Carexso
Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi said: “Under the directives of the UAE’s wise leadership, and renowned for its world-leading medical infrastructure, Abu Dhabi stands at the forefront of healthcare excellence, offering an unparalleled opportunity for advancement in healthcare for global partners. It was our utmost pleasure hosting the J.P. Morgan Asset Management Life Sciences Innovation Summit 2024 on the sidelines of Abu Dhabi Global Healthcare Week and we commend the winners for their pioneering efforts in driving impactful advancements in healthcare; their dedication to innovation not only transforms the landscape of medicine, but also holds the promise of improving lives worldwide.” 
Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are thrilled with the level of biotech passion and innovation that we observed at this year’s Summit in Abu Dhabi. The energy was truly palpable we are thrilled to announce Rayees Rahman as the winner of our first Life Sciences Innovation Summit. Harmonic Discovery’s approach embodies the next generation of drug discovery and development. We appreciate the time and effort of all participants and cannot wait for our next event in the region.”
Nabil Kobeissi, Chief Executive Officer of Blue Horizon Advisors, said: “As the main sponsor, we are committed to nurturing and fostering the growth of all 11 finalists in this vibrant biotech ecosystem. This Summit marks the beginning of a transformative journey, and we are confident that it will pave the way for a flourishing hub in the region. We are also pleased to announce that we will commit to invest in and partner with the winner, Harmonic Discovery, to support its future growth in the region.”
Sponsors for the event included J.P. Morgan Life Sciences Private Capital, J.P. Morgan Commercial Bank, Blue Horizon Advisors, United Al Saqer Group, Thermo Fisher Scientific, and Salam Capital. The Summit organisation, logistics and finalist recruitment were facilitated by Lyfebulb.
Of importance, at the Summit, Mr. Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City, announced that Masdar City Free Zone would award all 11 Finalists complimentary business licenses to further support their establishment in the region. Masdar City is one of the world’s most sustainable urban developments and innovation hubs with a growing focus on life science entrepreneurship in Abu Dhabi.

View original content:https://www.prnewswire.co.uk/news-releases/jp-morgan-life-sciences-private-capital-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit-302149186.html

Continue Reading

Artificial Intelligence

Congregating in the Lion City for a Win-Win Future of Intelligent Computing at the Global Data Center Facility Summit 2024

Published

on

congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024

SINGAPORE, May 17, 2024 /PRNewswire/ — On May 17, 2024, the Global Data Center Facility Summit 2024 was held in Singapore with the theme of “Power the Digital Era Forward.” At the summit, over 600 data center industry leaders, technical experts, and ecosystem partners gathered to discuss new trends and opportunities of the global data center industry in the intelligent computing era. The attendees also got to experience all-scenario, all-ecosystem, and all-service end-to-end (E2E) solutions, share innovative practices of green data centers in the Asia Pacific and Europe, and experience the exhibition vehicle to unveil the mystery of Outdoor PowerPOD that features one power system per container. By fully embracing the intelligent computing era, Huawei strives to power the digital era forward.

Seizing Opportunities Brought by AI and Jointly Building Green & Reliable Computing Infrastructure
At the opening speech, Charles Yang, Senior Vice President of Huawei and President of Marketing, Sales and Services, Huawei Digital Power, noted that since ChatGPT ushered in the AI era, large models keep pushing the limits of computing power and the intelligent computing industry is witnessing an unprecedented construction boom. As predicted, 100 GW will be added to the global data center installed capacity and the market value will exceed US$600 billion in the next five years.
According to Charles, with opportunities come challenges. The primary challenge concerning the data center industry is reliability and electricity. Data centers are scaling up from the MW-level to the GW-level. E2E reliability of data centers is becoming even more important than ever. In response to the opportunities, Huawei will work with customers and partners to expand the industry space.
Steering Data Centers to the AI Era with Product + Service + Ecosystem
During the summit, Sun Xiaofeng, President of Huawei Data Center Facility & Critical Power Business, delivered a speech titled “Power the Digital Era Forward. ” He stated that as AI large models are penetrating, the surging compute demands drive the expansive growth in data center.
To address the challenges, Huawei strives to build product + service + ecosystem E2E data center solutions that feature fast deployment, flexible cooling, green energy, and ultimate reliability.
Fast deployment: Data centers are fully modularized and prefabricated to ensure high quality and efficient construction.Flexible cooling: Air-liquid fusion and integrated cooling source emerges as the optimal cooling architecture for intelligent computing.Green energy: New generation-grid-load-storage integrated solution is built to ensure the sound operations of intelligent computing centers.Ultimate reliability: Data centers are safeguarded through reliable products and preventive protection.Currently, Huawei’s global service network covers more than 170 countries with over 1800 professional engineers, providing 24/7 technical support. With N+ flagship service centers, Huawei has built a one-hour service radius for its customers.
The ecosystem is a key part for a win-win future of intelligent computing. Huawei works with partners to develop comprehensive E2E solutions and provide customers with one-stop data center services.
During the summit, Huawei and the ASEAN Centre for Energy released a white paper on “Building Next Generation Data Center Facility in ASEAN.” The document provides insights into the status quo, challenges, and trends of data centers in the ASEAN region, and emphasizes that efficient and energy-saving products and solutions should be applied. It also proposes future-oriented policy recommendations for data center markets.
In the ecosystem exhibition area, Huawei showcased scenario-based solutions for large-, medium-, and small-sized data centers, and demonstrated data center consulting, design, integrated development, and delivery capabilities with dozens of ecosystem partners including CIMC, Weichai, CSCEC, and Huashi.
On a special note, the Huawei Outdoor PowerPOD exhibition vehicle made its global debut. The Huawei Outdoor PowerPOD features one power system per container, outdoor deployment, plug-and-play, and high protection rating and reliability. It has become the preferred choice for decoupling the power supply architecture.
A single tree cannot make a forest.
AI is presenting great opportunities. By delving into the industry, aggregating partner ecosystems, and making innovations applicable to transformations, Huawei will continue to help customers build reliable computing infrastructure, accelerating the industry to embrace AI and powering the digital era forward.
Photo – https://mma.prnewswire.com/media/2415818/Global_Data_Center_Facility_Summit_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024-302148973.html

Continue Reading

Artificial Intelligence

HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market

Published

on

hoya-group-company,-pentax-of-america,-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-u.s-market

WASHINGTON D.C., May 17, 2024 /PRNewswire/ — HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical) and MAGENTIQ-EYE Ltd., an AI medical device company, announced today their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and strategic partnerships.

Pending field trials and customer demonstrations to be conducted over the next several months, the companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO™ AI-assisted lesion detection device in the U.S.A. beginning October 1st, 2024. The system will be demonstrated at the upcoming Digestive Disease Week (DDW) in Washington D.C., U.S.A.
MAGENTIQ-COLO™ is a cutting-edge system for the detection of gastrointestinal lesions in colonoscopies. Successfully validated in an international multicenter, randomized, controlled trial (RCT) with 950 enrolled patients at 10 hospitals in Europe, United States and Israel, its outstanding diagnostic capabilities are setting new standards in endoscopic AI.
“We are excited to bring the MAGENTIQ-COLO™ device to the GI community in the U.S. Together with PENTAX Medical’s product portfolio, we are confident to provide a smart solution in colonoscopy and contribute further to colorectal cancer prevention”, says David Harrison, President PENTAX of America, Inc.
“Partnering with PENTAX Medical is an important milestone for us, as it opens new opportunities to introduce our game changing product to the U.S. market, benefiting doctors and their patients and saving more lives”, says Dror Zur, Founder & CEO of MAGENTIQ-EYE.
About MAGENTIQ-EYE Ltd.Founded in 2014, MAGENTIQ-EYE offers a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy, and saving more and more lives. www.magentiq.com 
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company’s mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community’s Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider’s experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support. Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles and helps improve endoscopy with smart innovations.
For more information: https://www.pentaxmedical.com
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of lifecare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels, and hard disk drives. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 36,000 people. For more information, please visit: https://www.hoya.com/en/

View original content:https://www.prnewswire.co.uk/news-releases/hoya-group-company-pentax-of-america-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-us-market-302148971.html

Continue Reading

Trending